natgillin/translations-raw huggingface dataset:
• rashes (including red spots or blotches sometimes with blistering and swelling of the skin), which may be allergic reactions, itching, changes in skin colour including darkening of the skin in patches
• izpuščaji (vključno z rdečimi pikami ali ogrci, včasih z mehurjasto in oteklo kožo), kar je lahko alergična reakcija, srbečica, sprememba obarvanosti kože, vključujoč temne lise
Uncommon side effects (These can affect 1 to 10 users in 1,000)
Občasni neželeni učinki (Prizadenejo lahko 1 do 10 od 1. 000 uporabnikov)
Children given emtricitabine experienced changes in skin colour including darkening of the skin in patches (very common) and anaemia (common).
Pri otrocih, ki so prejemali emtricitabin, so se pojavljale spremembe v obarvanosti kože, vključujoč temne lise (zelo pogosto) in anemija (pogosto).
Anaemia means the production of red blood cells is reduced, and a child may have symptoms of tiredness or breathlessness.
Anemija pomeni zmanjšano tvorbo rdečih krvnih telesc in pri otroku se lahko pojavijo znaki utrujenosti ali zadihanosti.
Medicines like Emtriva can cause lactic acidosis (excess lactic acid in the blood).
Zdravila, kot je Emtriva, lahko povzročijo laktično acidozo (preveliko količino mlečne kisline v krvi).
The following may be signs of lactic acidosis: • Deep, rapid breathing • Drowsiness • Nausea (feeling sick), vomiting and stomach pain If you notice any of these symptoms, tell your doctor immediately.
Znaki laktične acidoze so lahko: • globoko, naglo dihanje • dremavost • navzea (slabost), bruhanje in bolečine v trebuhu Če opazite katerega od teh simptomov, o tem nemudoma obvestite zdravnika.
Combination antiretroviral therapy (including Emtriva) may change your body shape, by changing the way body fat is distributed.
42 Kombinirano protiretrovirusno zdravljenje (vključno z zdravilom Emtriva) lahko povzroči spremembe telesne oblike zaradi sprememb v razporeditvi maščob.
You may lose fat from your legs, arms and face; gain fat around the abdomen (tummy) and internal organs; get larger breasts or fatty lumps on the back of the neck (‘ buffalo hump’).
Izgubite lahko maščevje na nogah, rokah in obrazu; pridobite maščevje na trebuhu in notranjih organih; lahko se vam povečajo prsi ali maščobna bula na tilniku (“ bivolja grba ”).
The cause and the long-term effects of these changes are not yet known.
Vzrok za te spremembe in njihov dolgoročni učinek še nista znana.
Combination antiretroviral therapy may also cause hyperlipaemia (increased fats in the blood) and resistance to insulin.
Kombinirano protiretrovirusno zdravljenje lahko povzroči hiperlipidemijo (povišana količina maščob v krvi) in odpornost na insulin.
If you get any of the side effects listed, or if you notice any side effects not listed in this leaflet, tell your doctor.
Če dobite kateregakoli od omenjenih neželenih učinkov ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
HOW TO STORE EMTRIVA
SHRANJEVANJE ZDRAVILA EMTRIVA
40 Do not use Emtriva after the expiry date which is stated on the bottle, blister pack and outer carton after {EXP}.
Zdravila Emtriva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki, pretisnih omotih in zunanji ovojnini poleg oznake {Uporabno do}.
What Emtriva contains
Kaj vsebuje zdravilo Emtriva
Capsule shell: gelatin, indigotine (E132), titanium dioxide (E171)
Lupina kapsule: želatina, indigotin (E132), titanov dioksid (E171)
Each capsule is printed with “ 200 mg” on the cap and “ GILEAD” and [Gilead logo] on the body in black ink.
Na vsaki kapsuli je s črnim črnilom na pokrovčku odtisnjeno “ 200 mg ” ter na telesu “ GILEAD ” in [Gilead logo].
Emtriva is also available as an oral solution for use in children and infants older than 4 months, patients who have difficulty in swallowing and patients with kidney problems.
Zdravilo Emtriva je na razpolago tudi v obliki peroralne raztopine, predvsem za uporabo pri otrocih in dojenčkih, starejših od 4 mesece, bolnikih, ki težko požirajo in bolnikih, ki imajo ledvične težave.
There is a separate Package Leaflet for Emtriva 10 mg/ ml oral solution.
Za uporabo peroralne raztopine Emtriva 10 mg/ ml je na voljo posebno navodilo za uporabo.
Marketing Authorisation Holder and Manufacturer
43 Imetnik dovoljenja za promet z zdravilom in izdelovalec
Gilead Sciences Limited Unit 13, Stillorgan Industrial Park Blackrock County Dublin Ireland
Gilead Sciences Limited Unit 13, Stillorgan Industrial Park Blackrock County Dublin Irska
Cork Ireland
Gilead Sciences Limited IDA Business & Technology Park Carrigtohill County Cork Irska
41 For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom:
España Gilead Sciences, S. L.
44 España Gilead Sciences, S. L.
This leaflet was last approved in MM/ YYYY.
Navodilo je bilo odobreno MM/ YYYY.
Emtriva oral solution is particularly suitable for people who have difficulty in swallowing Emtriva hard capsules.
Peroralna raztopina Emtriva je še zlasti primerna za bolnike, ki imajo težave s požiranjem trdih kapsul zdravila Emtriva.
• If you are allergic (hypersensitive) to emtricitabine or any of the other ingredients of Emtriva 10 mg/ ml oral solution listed at the end of this leaflet.
• Če ste alergični (preobčutljivi) na emtricitabin ali katerokoli sestavino peroralne raztopine Emtriva 10 mg/ ml, ki so navedene na koncu tega navodila.
Take special care with Emtriva
Bodite posebno pozorni pri uporabi zdravila Emtriva
Before starting treatment, your doctor may order blood tests to assess kidney function
Pred začetkom zdravljenja bo zdravnik morda naredil krvne preiskave, 46 da bo ocenil delovanje ledvic in vam morda svetoval, da jemljete zmanjšani odmerek peroralne raztopine Emtriva ali predpisal trde kapsule Emtriva.
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
47 Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta.
45 Do not stop your treatment without contacting your doctor.
Ne prekinite zdravljenja brez posvetovanja z zdravnikom.
Important information about some of the ingredients of Emtriva oral solution
Pomembne informacije o nekaterih sestavinah peroralne raztopine Emtriva
This medicine contains 254 mg of sodium per dose which should be taken into consideration by patients on a controlled sodium diet.
To zdravilo vsebuje 254 mg natrija na odmerek, kar morajo upoštevati bolniki, ki so na dieti z nadzorovanim vnosom natrija.
Your doctor will advise the correct amount of Emtriva oral solution to be taken.
Vaš zdravnik vam bo predpisal ustrezno količino peroralne raztopine Emtriva, ki jo morate jemati.
• Infants, children and adolescents weighing 40 kg or less: the dose of Emtriva 10 mg/ ml oral solution is calculated according to your body weight.
Primeri telesne mase in
Examples of body weight and the corresponding doses and volumes of the oral solution to be taken each day are given in the table below:
48 pripadajočih odmerkov ter volumnov peroralne raztopine, ki jih je treba jemati dnevno, so navedeni v spodnji tabeli.
46 Per day Body weight (kg)
Dnevno Telesna masa (kg)
How much 10 mg/ ml (ml)
Koliko 10 mg/ ml peroralne raztopine je treba vzeti (ml)
If it is almost time for your next dose anyway, forget about the missed dose.
49 Če je že skoraj čas za vaš naslednji odmerek, pozabljenega odmerka ne vzemite.
47 If you are sick (vomit) If it’ s less than an hour since you took Emtriva, take another dose.
Če vam je slabo (če bruhate) Če je manj kot ena ura odkar ste vzeli zdravilo Emtriva, vzemite še en odmerek.
Common side effects (These can affect 1 to 10 users in 100)
Pogosti neželeni učinki (Prizadenejo lahko 1 do 10 od 100 uporabnikov)
Tests may also show:
50 Preiskave lahko kažejo tudi:
48 • liver and pancreas problems
• težave z jetri in trebušno slinavko
Combination antiretroviral therapy (including Emtriva) may change your body shape, by changing the way body fat is distributed.
Kombinirano protiretrovirusno zdravljenje (vključno z zdravilom Emtriva) lahko povzroči spremembe telesne oblike zaradi sprememb v razporeditvi maščob.
Do not use Emtriva after the expiry date which is stated on the bottle and outer carton after {EXP}.
Zdravila Emtriva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na plastenki in zunanji ovojnini poleg oznake {Uporabno do}.
Store in a refrigerator (2°C – 8°C) until opened.
Shranjujte v hladilniku (2 °C – 8 °C), dokler ne odprete.
After opening the bottle, do not store above 25ºC.
Po odprtju shranjujte plastenko pri temperaturi do 25 °C.
If there is any solution left in the bottle after 45 days, this should be discarded according to local requirements or returned to the pharmacy.
51 Če vam je po 45 dneh ostalo še kaj raztopine v plastenki, morate to raztopino uničiti v skladu z lokalnimi predpisi ali vrniti nazaj v lekarno.
One ml of Emtriva oral solution contains 10 mg emtricitabine (10 mg/ ml).
En mililiter peroralne raztopine Emtriva vsebuje 10 mg emtricitabina (10 mg/ ml).
• The other ingredients are: cotton candy flavouring, disodium edetate, hydrochloric acid, methyl parahydroxybenzoate (E218), propylene glycol, propyl parahydroxybenzoate (E216), sodium hydroxide, sodium phosphate monobasic hydrate, sunset yellow (E110), purified water, xylitol (E967).
• Pomožne snovi so: aroma sladkorne pene (Cotton candy flavouring), dinatrijev edetat, klorovodikova kislina, metilparahidroksibenzoat (E218), propilenglikol, propilparahidroksibenzoat (E216), natrijev hidroksid, natrijev dihidrogenfosfat hidrat, oranžno FCF (E110), prečiščena voda, ksilitol (E967).
These are only suitable for patients who weigh at least 33 kg and can swallow hard capsules.
Zdravilo Emtriva je na razpolago tudi v obliki trdih kapsul, kar je namenjeno bolnikom, ki tehtajo vsaj 33 kg in lahko pogoltnejo trdo kapsulo.
Č eská republika Gilead Sciences International Ltd Tel: + 44 (0) 20 7136 8820
52 Česká republika Gilead Sciences International Ltd Tel: + 44 (0) 20 7136 8820
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu/.
53 Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMEA) http: // www. emea. europa. eu /.
It is available as vials containing a powder to be made up into a solution for injection, and as prefilled syringes containing a solution for injection.
Na voljo je v vialah, ki vsebujejo prašek, iz katerega se pripravi raztopina za injiciranje, ter v napolnjenih injekcijskih brizgah, ki vsebujejo raztopino za injiciranje.
Each vial or syringe contains either 25 or 50 mg of etanercept.
Vsaka viala oziroma brizga vsebuje 25 mg oziroma 50 mg etanercepta.
Enbrel is an anti-inflammatory medicine.
Zdravilo Enbrel je protivnetno zdravilo.
It is used for the treatment of the following diseases: • moderate to severe rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults.
Uporablja se za zdravljenje naslednjih obolenj: • zmernega do hudega revmatoidnega artritisa (obolenje imunskega sistema, ki povzroča vnetje sklepov) pri odraslih.
Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments.
Zdravilo Enbrel se uporablja skupaj z metotreksatom (zdravilom, ki učinkuje na imunski sistem) pri odraslih z zmernim do hudim obolenjem, ki se niso zadostno odzvali na druge načine zdravljenja.
Enbrel can also be used on its own if methotrexate is not suitable for the patient.
Zdravilo Enbrel se lahko uporablja kot samostojno zdravilo, če zdravljenje z metotreksatom za bolnika ni primerno.
It can also be used in patients with severe rheumatoid arthritis who have not taken methotrexate before; • polyarticular juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints) in children aged four to 17 years who have not responded adequately to or cannot take methotrexate; • psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) in adults who have not responded adequately to other treatments; • severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments; • plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease and in children from the age of eight years with chronic (long-term) severe disease.
Lahko pa se uporablja tudi pri bolnikih s hudim revmatoidnim artritisom, ki pred tem metotreksata niso prejemali; • poliartikularnega juvenilnega idiopatskega artritisa (redko obolenje pri otrocih, pri katerem se vnetje pojavlja na več sklepih) pri otrocih, starih od 4 do 17 let, ki se niso zadostno odzvali na zdravljenje z metotreksatom ali pa metotreksata ne prenašajo; • psoriatičnega artritisa (obolenje, ki povzroča rdeče, luskaste zaplate na koži in vnetje sklepov) pri odraslih, ki se niso zadostno odzvali na druge načine zdravljenja; • hudega ankilozirajočega spondilitisa (obolenje, ki povzroča vnetje sklepov v hrbtenici) pri odraslih, ki se niso zadostno odzvali na druge načine zdravljenja; • psoriaze v plakih (obolenje, ki povzroča rdeče, luskaste zaplate na koži) pri odraslih z zmernim do hudim obolenjem in otrocih po osmem letu starosti s kroničnim (dolgotrajnim) hudim obolenjem.
Enbrel is used in patients who have not responded to or cannot receive other treatments for this disease.
Zdravilo Enbrel se uporablja pri bolnikih, ki se niso zadostno odzvali na druga zdravljenja ali pa teh ne prenašajo.
Enbrel treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Enbrel is used to treat.
Zdravljenje z zdravilom Enbrel lahko uvede in nadzoruje le zdravnik specialist, ki ima izkušnje z diagnosticiranjem in zdravljenjem obolenj, za zdravljenje katerih se uporablja zdravilo Enbrel.
Enbrel is given by injection under the skin.
Zdravilo Enbrel se injicira v podkožje.
For adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week.
Običajni priporočeni odmerek za odrasle je 25 mg dvakrat na teden ali 50 mg enkrat na teden.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
Pri psoriazi se zdravilo lahko daje tudi v 50- miligramskem odmerku dvakrat na 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel.
Reproduction is authorised provided the source is acknowledged. in psoriasis.
Reproduction is authorised provided the source is acknowledged. teden v obdobju do 12 tednov.
For children, the dose depends on body weight.
Pri otrocih je odmerek odvisen od telesne mase.
The patient or carer can give the injection if they have been trained appropriately.
Zdravilo si lahko injicira bolnik sam ali njegov negovalec, pod pogojem, da sta bila za to ustrezno usposobljena.
Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine.
Bolnikom, ki uporabljajo zdravilo Enbrel, je treba dati posebno opozorilno kartico, ki povzema najpomembnejše informacije o varnosti zdravila.
The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF).
Etanercept, zdravilna učinkovina v zdravilu Enbrel, je beljakovina, ki je bila zasnovana tako, da v telesu zavira aktivnost kemičnega prenašalca, imenovanega tumorje nekrotizirajoči faktor (TNF).
This messenger is found at high levels in patients with the diseases that Enbrel is used to treat.
Ta prenašalec je v velikih koncentracijah prisoten pri bolnikih z obolenji, za zdravljenje katerih se uporablja zdravilo Enbrel.
By blocking TNF, etanercept improves the inflammation and other symptoms of the diseases.
Z zaviranjem TNF etanercept izboljša stanje vnetij in druge simptome obolenj.
Etanercept is produced by a method known as ‘ recombinant DNA technology’: it is made by a cell that has received a gene (DNA), which makes it able to produce etanercept.
Etanercept proizvajajo z metodo, znano kot „ tehnologija rekombinantne DNK “, pri kateri celica prejme gen (DNK), s katerim lahko tvori etanercept.
Enbrel has been studied in five main studies in rheumatoid arthritis, involving about 2,200 patients and lasting from three months to two years.
Zdravilo Enbrel so pri revmatoidnem artritisu raziskovali v petih večjih študijah, v katerih je sodelovalo približno 2 200 bolnikov, trajale pa so od treh mesecev do dveh let.
Three studies compared Enbrel with placebo (a dummy treatment) in patients who had taken anti-arthritis medicines in the past.
V treh študijah so pri bolnikih, ki so v preteklosti prejemali zdravila za zdravljenje artritisa, zdravilo Enbrel primerjali s placebom (zdravilom brez zdravilne učinkovine).
One of these studies examined Enbrel’ s effects as an add-on to methotrexate in 89 patients.
V eni od teh študij so pri 89 bolnikih proučevali učinke zdravila Enbrel, ki so ga uporabili kot dodatek metotreksatu.
In the fourth study, Enbrel was compared with methotrexate in 632 patients who had not taken methotrexate before.
V četrti študiji so pri 632 bolnikih, ki pred tem metotreksata niso prejemali, zdravilo Enbrel primerjali z metotreksatom.
The fifth study compared the effectiveness of Enbrel, methotrexate and a combination of both in 686 patients.
V peti študiji so pri 686 bolnikih primerjali učinkovitost zdravila Enbrel, metotreksata ter kombinacije obeh zdravil.
In all studies, the main measure of effectiveness was the improvement of the symptoms of arthritis.
V vseh študijah je bilo glavno merilo učinkovitosti izboljšanje simptomov artritisa.
Enbrel was compared with placebo in 51 children with polyarticular juvenile idiopathic arthritis, 205 adults with psoriatic arthritis, 357 adults with ankylosing spondylitis, and 1,263 adults and 211 children with plaque psoriasis.
Zdravilo Enbrel so primerjali s placebom pri 51 otrocih s poliartikularnim juvenilnim idiopatskim artritisom, 205 odraslih s psoriatičnim artritisom, 357 odraslih z ankilozirajočim spondilitisom in 1 263 odraslih ter 211 otrocih s psoriazo v plakih.
The main measure of effectiveness was the change in symptoms after three to four months.
Glavno merilo učinkovitosti je bila sprememba simptomov po treh do štirih mesecih.
Overall, in the studies of rheumatoid arthritis, about two-thirds of the patients receiving Enbrel had a reduction in symptoms of 20% or more after three months.
V vseh študijah revmatoidnega artritisa je pri približno dveh tretjinah bolnikov, ki so prejemali zdravilo Enbrel, po treh mesecih prišlo do zmanjšanja simptomov za 20% ali več.
This compared with 23 to 33% of the patients receiving placebo.
Ta delež je pri bolnikih, ki so prejemali placebo, znašal 23 do 33%.
In the study of patients who had not taken methotrexate before, those receiving 25 mg Enbrel twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months.
V študiji, v kateri so sodelovali bolniki, ki pred tem metotreksata niso prejemali, so po 12 in 24 mesecih pri bolnikih, ki so prejemali 25 mg zdravila Enbrel dvakrat na teden, ugotovili manj poškodb sklepov, kot pri tistih, ki so prejemali samo metotreksat.
In the fifth study, Enbrel on its own or in combination with methotrexate was shown to be more effective than methotrexate alone.
V peti študiji se je izkazalo, da je bilo zdravilo Enbrel, ki so ga dajali samostojno ali v kombinaciji z metotreksatom, bolj učinkovito kot metotreksat, uporabljen kot samostojno zdravilo.
For all other diseases studied, Enbrel produced a greater improvement in symptoms than placebo.
Pri vseh drugih obolenjih, ki so jih raziskovali, je zdravilo Enbrel povzročilo večje izboljšanje simptomov kot placebo.
The most common side effects with Enbrel (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling), infections (including colds, and lung, bladder and skin infections).
Najpogostejši neželeni učinki zdravila Enbrel (opaženi pri več kot 1 od 10 bolnikov) so reakcije na mestu injiciranja (vključno s krvavitvami, podplutbami, rdečino, srbenjem, bolečino in oteklino), okužbe (vključno s prehladi in okužbami pljuč, mehurja in kože).
Patients developing a serious infection should stop Enbrel treatment.
Bolniki, pri katerih se pojavi huda okužba, morajo prenehati z uporabo zdravila Enbrel.
Similar side effects are seen in adults and in children.
Opaženi neželeni učinki so pri odraslih in otrocih podobni.
For the full list of all side effects reported with Enbrel, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Enbrel, glejte navodilo za uporabo.
Enbrel should not be used in people who may be hypersensitive (allergic) to etanercept or any of the other ingredients.
Zdravila Enbrel ne smejo uporabljati osebe, ki utegnejo bili preobčutljive za (alergične na) etanercept ali katero koli drugo sestavino zdravila.
Enbrel must not be used in patients who have or are at risk of sepsis (serious blood infection), or in patients with infections.
Zdravila Enbrel ne smejo uporabljati bolniki, ki imajo sepso (hudo okužbo krvi) oziroma pri katerih obstaja tveganje za razvoj sepse ali bolniki z okužbami.
Before using Enbrel, doctors must check that the patient is free of infection, including tuberculosis.
Pred uporabo zdravila Enbrel mora zdravnik preveriti, da bolnik nima nobenih okužb in da ni okužen s tuberkulozo.
The Committee for Medicinal Products for Human Use (CHMP) decided that Enbrel’ s benefits are greater than its risks for treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Enbrel pri zdravljenju revmatoidnega artritisa, poliartikularnega juvenilnega idiopatskega artritisa, psoriatičnega artritisa, ankilozirajočega spondilitisa in psoriaze v plakih večje od z njim povezanih tveganj.
The Committee recommended that Enbrel be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Enbrel odobri dovoljenje za promet.
The European Commission granted a marketing authorisation valid throughout the European Union for Enbrel to Wyeth Europa Ltd on 3 February 2000.
Evropska komisija je dovoljenje za promet z zdravilom Enbrel, veljavno po vsej Evropski uniji, odobrila družbi Wyeth Europa Ltd dne 3. februarja 2000.
The marketing authorisation was renewed on 3 February 2005.
Dovoljenje za promet z zdravilom je bilo obnovljeno dne 3. februarja 2005.
2/ 3 The full EPAR for Enbrel can be found here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Enbrel je na voljo tukaj.
Subcutaneous use
Podkožna uporaba
powder: vial (glass); solvent: syringe (glass)
prašek: steklena viala; vehikel: steklena injekcijska brizga
4 vials + 4 pre-filled syringes + 8 swabs
4 viale + 4 napolnjene injekcijske brizge + 8 alkoholnih tamponov
powder: vial (glass)
prašek: steklena viala;
4 vials + 8 swabs
4 viale + 8 alkoholnih tamponov
4 vials + 4 pre-filled syringes + 4 needles + 4 vial adaptors + 8 swabs
4 viale + 4 napolnjene injekcijske brizge + 4 igle + 4 adapterje za viale + 8 alkoholnih tamponov
8 vials + 8 pre-filled syringes + 8 needles + 8 vial adaptors + 16 swabs
8 vial + 8 napolnjenih injekcijskih brizg + 8 igel + 8 adapterje za viale + 16 alkoholnih tamponov
24 vials + 24 pre-filled syringes + 24 needles + 24 vial adaptors + 48 swabs
24 vial + 24 napolnjenih injekcijskih brizg + 24 igel + 24 adapterje za viale + 48 alkoholnih tamponov
2 vials + 4 swabs
2 viale + 4 alkoholnih tamponov
12 vials + 24 swabs
12 viale + 24 alkoholnih tamponov
2 vials + 2 pre-filled syringes + 2 needles + 2 vial adaptors + 4 swabs
2 viale + 2 napolnjene injekcijske brizge + 2 igle + 2 adapterje za viale + 4 alkoholnih tamponov